BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28815582)

  • 1. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression.
    Wu YH; Huang YF; Chang TH; Chou CY
    Int J Cancer; 2017 Dec; 141(11):2305-2317. PubMed ID: 28815582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
    Wu YH; Huang YF; Chen CC; Chou CY
    Cell Death Dis; 2019 Apr; 10(4):322. PubMed ID: 30975980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
    Rada M; Nallanthighal S; Cha J; Ryan K; Sage J; Eldred C; Ullo M; Orsulic S; Cheon DJ
    Oncogene; 2018 Aug; 37(35):4809-4820. PubMed ID: 29769618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
    Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
    Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
    Wu YH; Chang TH; Huang YF; Chen CC; Chou CY
    Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
    Wu YH; Chang TH; Huang YF; Huang HD; Chou CY
    Oncogene; 2014 Jun; 33(26):3432-40. PubMed ID: 23934190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The downregulation of miR-509-3p expression by collagen type XI alpha 1-regulated hypermethylation facilitates cancer progression and chemoresistance via the DNA methyltransferase 1/Small ubiquitin-like modifier-3 axis in ovarian cancer cells.
    Wu YH; Huang YF; Wu PY; Chang TH; Huang SC; Chou CY
    J Ovarian Res; 2023 Jun; 16(1):124. PubMed ID: 37386587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of NF-κB by SOD2 promotes the aggressiveness of lung adenocarcinoma by modulating NKX2-1-mediated IKKβ expression.
    Chen PM; Wu TC; Wang YC; Cheng YW; Sheu GT; Chen CY; Lee H
    Carcinogenesis; 2013 Nov; 34(11):2655-63. PubMed ID: 23784082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COL11A1 activates cancer-associated fibroblasts by modulating TGF-β3 through the NF-κB/IGFBP2 axis in ovarian cancer cells.
    Wu YH; Huang YF; Chang TH; Chen CC; Wu PY; Huang SC; Chou CY
    Oncogene; 2021 Jul; 40(26):4503-4519. PubMed ID: 34117361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray‑based analysis of COL11A1 and TWIST1 as important differentially‑expressed pathogenic genes between left and right‑sided colon cancer.
    Su C; Zhao J; Hong X; Yang S; Jiang Y; Hou J
    Mol Med Rep; 2019 Nov; 20(5):4202-4214. PubMed ID: 31545476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.
    Cho MS; Rupaimoole R; Choi HJ; Noh K; Chen J; Hu Q; Sood AK; Afshar-Kharghan V
    J Immunol; 2016 Feb; 196(3):1412-8. PubMed ID: 26718342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
    Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
    Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
    Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
    Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1.
    Liu Y; Mayo MW; Xiao A; Hall EH; Amin EB; Kadota K; Adusumilli PS; Jones DR
    Mol Cell Biol; 2015 Jan; 35(1):303-17. PubMed ID: 25368381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma.
    Tan M; Asad M; Heong V; Wong MK; Tan TZ; Ye J; Kuay KT; Thiery JP; Scott C; Huang RY
    Mol Oncol; 2019 Apr; 13(4):757-780. PubMed ID: 30548372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of COL11A1 by PRRX1 promotes tumor progression and radioresistance in ovarian cancer.
    Zhu M; Ye C; Wang J; Yang G; Ying X
    Int J Radiat Biol; 2021; 97(7):958-967. PubMed ID: 33970764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.
    Hernandez L; Hsu SC; Davidson B; Birrer MJ; Kohn EC; Annunziata CM
    Cancer Res; 2010 May; 70(10):4005-14. PubMed ID: 20424119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD10 expression is enhanced by Twist1 and associated with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro and in vivo.
    Lee KW; Sung CO; Kim JH; Kang M; Yoo HY; Kim HH; Um SH; Kim SH
    Int J Cancer; 2015 Jan; 136(2):310-21. PubMed ID: 24895167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase.
    Zhang L; Cui R; Cheng X; Du J
    Cancer Res; 2005 Jan; 65(2):457-64. PubMed ID: 15695387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.